ePrints

Continuous infusional combination chemotherapy in inflammatory breast cancer: a phase II study

Lookup NU author(s): Dr Mark Verrill

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

Despite the introduction of systemic chemotherapy, inflammatory breast cancer (IBC) remains a disease with a poor prognosis. We performed this phase II study to evaluate the efficacy of infusional chemotherapy as initial treatment in patients with IBC. Fifty-four patients with newly diagnosed IBC were offered infusional chemotherapy and 34 accepted. The schedule consisted of continuous infusional ECF (bolus epirubicin and cisplatin, substituted by carboplatin or cyclophosphamide in some patients) plus continuous 5-FU, given three weekly for six cycles. Following chemotherapy patients went on to have surgery and/or radiotherapy. The chemotherapy was well tolerated and resulted in an overall response rate of 79% with 35% of patients achieving a complete clinical response. The median response duration, time to progression and overall survival were 12 months (4-89+ months), 12 months (4-89+ months) and 23 months (7-89+ months), respectively. Patients had a 5 year disease free and overall survival of 11% and 29%, respectively. Infusional ECF is well tolerated and achieves a high clinical response rate in patients with IBC, but survival results do not appear to be superior to those achieved with conventional bolus chemotherapy schedules. (C) 2000 Harcourt Publishers Ltd.

Publication metadata

Author(s): Verrill MW; de Boer RH; Saini A; Johnston SRD; O'Brien MER; Ellis PA; Prendiville JA; Walsh G; Ashley S; Smith IE

Publication type: Article

Publication status: Published

Journal: The Breast

Year: 2000

Volume: 9

Issue: 3

Pages: 149-155

ISSN (print): 0960-9776

ISSN (electronic): 1532-3080

Publisher: Churchill Livingstone

URL: http://dx.doi.org/10.1054/brst.1999.0158

DOI: 10.1054/brst.1999.0158

Altmetrics

Share